Herceptin Biosimilar is Effective Treatment Option for Treating Cancer Patients

 

Herceptin Biosimilar
Herceptin Biosimilar 

The first Herceptin Biosimilar was approved by the FDA in December 2017. It is a copycat of the reference product Herceptin. Other biosimilars include Ontruzant, Herzuma, and Biocon's Ogivri. Recently, the FDA approved a biosimilar version of the cancer drug Herceptin.  Its off-patent status in Europe means that it can be sold over-the-counter since January 2015. Trazimera, another biosimilar, is approved by the FDA to treat HER2-positive breast and gastric cancers. It is the fourth biosimilar version of Herceptin. It has similar side effects to Herceptin, including rash, nausea, and congestive heart failure. However, it may have higher heart risks and has been rejected by the European Committee for Medicinal Products (ECMP).

The global Herceptin Biosimilar Market size is estimated to be valued at US$ 1.3 billion in 2020 and is expected to exhibit a CAGR of 24.5 % over the forecast period (2020-2027).

The key to biosimilar acceptance is the ability to build trust among oncologists, payers, and patients. The researchers concluded that biosimilars were as effective as Herceptin but are cheaper than its counterpart. This is important because IV Herceptin can be very expensive. In addition, patients will benefit from subcutaneous trastuzumab administration because of its ease of administration. These benefits will encourage healthcare providers and patients to switch to biosimilars.

Several pharmaceutical companies are currently developing biosimilar versions of Herceptin. For instance, ABP 980 by Synthon is a biosimilar to Herceptin. Upon approval, it could provide a viable alternative treatment option for patients with HER2-positive early breast cancer. These biosimilars have the potential to be significant players in the global herceptin market. An increasing number of cancer patients worldwide will drive the demand for herceptin biosimilars. Twenty-six percent of patients reported that their treating oncologist briefed them on biosimilars. Another small percentage of patients received biosimilar information from chemotherapy nurses and advanced practice practitioners.

Comments

Popular posts from this blog

Axillary Crutches Are One of the Most Common Walking Aid Used By Patient for Suffering from Mobility Issues

Printed Electronics a Printing Technology Used To Produce Variety of Electronic Goods

Nursing Care Services helps in Early Recognition of Patient Condition and this May help to Improve the Patient's Outcomes